Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PH-797804 effect on sputum markers after LPS challenge
NCT02084485Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2006
- Primary completion
- Mar 2008
- Modality
- Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing PH-797804 with Placebo (2 arms). Primary endpoints: Sputum Cell Counts (Neutrophils) and Sputum Cytokines. Started Sep 2006; status: completed.
02
Drugs
PH-797804
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02084485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084485.